Citius Pharmaceuticals, Inc. (CTXR) financial statements (2020 and earlier)

Company profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments389301 
Cash and cash equivalents389301 
Receivables  1    
Prepaid expense000010 
Total current assets:3810311 
Noncurrent Assets
Operating lease, right-of-use asset11
Leveraged leases, net investment in leveraged leases disclosure, investment in leveraged leases1 
Property, plant and equipment00000  
Intangible assets, net (including goodwill)222220
Goodwill22222  
Intangible assets, net (excluding goodwill)     0 
Other undisclosed noncurrent assets1818191919  
Total noncurrent assets:22212121210 
TOTAL ASSETS:25293124221 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3432310
Accounts payable2321110
Accrued liabilities000110 
Employee-related liabilities11111  
Interest and dividends payable00000  
Debt0000  0
Derivative instruments and hedges, liabilities    21 
Due to related parties   000 
Other undisclosed current liabilities    1 0
Total current liabilities:4532510
Noncurrent Liabilities
Long-term debt and lease obligation1      
Operating lease, liability1 
Total noncurrent liabilities:1      
Total liabilities:5532510
Stockholders' equity
Stockholders' equity attributable to parent, including:2024282217(1)(0)
Common stock0000000
Additional paid in capital808068503480
Accumulated deficit(60)(56)(40)(28)(17)(9) 
Other undisclosed stockholders' equity attributable to parent      (0)
Total stockholders' equity:2024282217(1)(0)
TOTAL LIABILITIES AND EQUITY:25293124221 

Income statement (P&L) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2013
Revenues001    
Other operating income  1    
Other income0     
Cost of revenue
(Cost of Goods and Services Sold)
  (0)(0)   
Gross profit:001(0)   
Operating expenses(16)(16)(14)(10)(7)(3)(0)
Other undisclosed operating income (loss)(0)(0)(1)0   
Operating loss:(16)(16)(14)(10)(7)(3)(0)
Nonoperating income (expense)001(0)(1)0 
Investment income, nonoperating00     
Debt instrument, convertible, beneficial conversion feature  22   
Other nonoperating income    00 
Interest and debt expense(0)(0)0(1)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(16)(16)(12)(11)(8)(3)(0)
Other undisclosed income (loss) from continuing operations before income taxes3131(0)100 
Income (loss) before gain (loss) on sale of properties:1516(13)(10)(8)(3)(0)
Other undisclosed net loss(31)(31)     
Net loss:(16)(16)(13)(10)(8)(3)(0)
Other undisclosed net loss attributable to parent(0)      
Net loss available to common stockholders, diluted:(16)(16)(13)(10)(8)(3)(0)

Comprehensive Income ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2013
Net loss:(16)(16)(13)(10)(8)(3)(0)
Comprehensive loss, net of tax, attributable to parent:(16)(16)(13)(10)(8)(3)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: